1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

$Thumbnail for Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2$

ABCL - 619

Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2

Jon Ukropec

Poster Presenter: Jon Ukropec

$Thumbnail for A Multicenter, Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma (BCL): Updated Safety and Efficacy Results$

ABCL - 629

A Multicenter, Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma (BCL): Updated Safety and Efficacy Results

Saurabh Dahiya

Poster Presenter: Saurabh Dahiya

SOHO 2026 Annual Meeting

Posters by Session

Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2

A Multicenter, Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma (BCL): Updated Safety and Efficacy Results

Diminishing Gains in Non-Hodgkin Lymphoma Mortality in the United States: A Joinpoint Analysis of the Rituximab and COVID-19 Eras (1999-2024)

Safety and Efficacy of Polatuzumab Vedotin Combined with Bendamustine and Rituximab in Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Real-World Outcomes of Dose-Modified Polatuzumab Vedotin-R-CHP in Older Patients With High-Risk Diffuse Large B-Cell Lymphoma: A Retrospective Study From Northern India

Antigen Escape in Relapsed/Refractory Large B-Cell Lymphoma: A Case Series of CD20 Expression Loss After CD20-Directed Therapy

DLBCL AdaptIQ: A Molecular-Adaptive Clinical Decision Support System for Personalized Regimen Selection and Real-Time Clinical Trial Matching: Development and Dataset Validation in Diffuse Large B-Cell Lymphoma

Two-Year Outcomes of Molecularly Tailored R-CHOP-X in Newly Diagnosed DLBCL

EBV-Positive Sinonasal Plasma Cell Neoplasms: A Case Series with Favorable Outcomes in Elderly Males